These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35975371)

  • 21. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
    Hu P; Xuan Q; Hu B; Lu L; Wang J; Qin YH
    Int J Biol Sci; 2012; 8(5):663-71. PubMed ID: 22606047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis.
    Levin A
    Semin Dial; 2003; 16(2):101-5. PubMed ID: 12641872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease.
    Unsal A; Kose Budak S; Koc Y; Basturk T; Sakaci T; Ahbap E; Sinangil A
    Kidney Blood Press Res; 2012; 36(1):55-64. PubMed ID: 22854270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications.
    Calò LA; Vertolli U; Pagnin E; Ravarotto V; Davis PA; Lupia M; Naso E; Maiolino G; Naso A
    Life Sci; 2016 Mar; 148():80-5. PubMed ID: 26872982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Dietary Phosphorous Restriction on Fibroblast Growth 2 Factor-23 and sKlotho Levels in Patients with Stages 1-2 Chronic Kidney Disease.
    Saxena A; Sachan T; Gupta A; Kapoor V
    Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac Changes and Their Association with Fetuin-A and Fibroblast Growth Factor-23 in Children with Chronic Kidney Disease.
    Mudi A; Ntsinjana H; Dickens C; Levy C; Ballot D
    Nephron; 2017; 136(3):233-242. PubMed ID: 28402974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).
    Ix JH; Katz R; Kestenbaum BR; de Boer IH; Chonchol M; Mukamal KJ; Rifkin D; Siscovick DS; Sarnak MJ; Shlipak MG
    J Am Coll Cardiol; 2012 Jul; 60(3):200-7. PubMed ID: 22703926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast growth factor-23 and cardiovascular events in CKD.
    Scialla JJ; Xie H; Rahman M; Anderson AH; Isakova T; Ojo A; Zhang X; Nessel L; Hamano T; Grunwald JE; Raj DS; Yang W; He J; Lash JP; Go AS; Kusek JW; Feldman H; Wolf M;
    J Am Soc Nephrol; 2014 Feb; 25(2):349-60. PubMed ID: 24158986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
    Lioufas NM; Pedagogos E; Hawley CM; Pascoe EM; Elder GJ; Badve SV; Valks A; Toussaint ND;
    Am J Nephrol; 2020; 51(3):201-215. PubMed ID: 32023606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease.
    Negri AL
    Int Urol Nephrol; 2014 Jan; 46(1):9-17. PubMed ID: 23296792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.
    Jovanovich A; Ix JH; Gottdiener J; McFann K; Katz R; Kestenbaum B; de Boer IH; Sarnak M; Shlipak MG; Mukamal KJ; Siscovick D; Chonchol M
    Atherosclerosis; 2013 Nov; 231(1):114-9. PubMed ID: 24125420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additional prognostic value of electrocardiographic left ventricular hypertrophy in traditional cardiovascular risk assessments in chronic kidney disease.
    Tanaka F; Komi R; Nakamura M; Tanno K; Onoda T; Ohsawa M; Sakata K; Omama S; Ogasawara K; Ishibashi Y; Yonekura Y; Itai K; Kuribayashi T; Kikuchi Y; Ishigaki Y; Okayama A; Asahi K;
    J Hypertens; 2020 Jun; 38(6):1149-1157. PubMed ID: 32371805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner.
    Yan L; Mathew L; Chellan B; Gardner B; Earley J; Puri TS; Hofmann Bowman MA
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1399-411. PubMed ID: 24855059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy.
    Canziani ME; Tomiyama C; Higa A; Draibe SA; Carvalho AB
    Blood Purif; 2011; 31(1-3):26-32. PubMed ID: 21135546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of fibroblast growth factor 23 and malnutrition in chronic kidney disease patients on maintenance hemodialysis.
    Chaudhary R; Manocha R; Arora A
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of left ventricular hypertrophy in chronic kidney disease: an echocardiographic evaluation.
    Sambi RS; Gaur AK; Hotchandani R; Aggarwal KK; Kaur S; Gupta M; Jain S; Krishna CK; Chopra HK; Anand V; Srivastava S; Gupta R; Parashar SK
    Indian Heart J; 2011; 63(3):259-68. PubMed ID: 22734347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Excess risk of cardiovascular events in patients in the United States vs. Japan with chronic kidney disease is mediated mainly by left ventricular structure and function.
    Imaizumi T; Fujii N; Hamano T; Yang W; Taguri M; Kansal M; Mehta R; Shafi T; Taliercio J; Go A; Rao P; Hamm LL; Deo R; Maruyama S; Fukagawa M; Feldman HI;
    Kidney Int; 2023 May; 103(5):949-961. PubMed ID: 36738890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Left Ventricular Function and Geometry of Children with Chronic Kidney Disease (CKD) in a Resource-Poor Setting of Africa.
    Adiele DK; Okafor HU; Ojinnaka NC
    West Afr J Med; 2022 Oct; 39(10):1095-1103. PubMed ID: 36260934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left-ventricular hypertrophy and renal outcome in hypertensive patients in primary-care.
    Ravera M; Noberasco G; Signori A; Re M; Filippi A; Cannavò R; Weiss U; Cricelli C; Deferrari G; Paoletti E
    Am J Hypertens; 2013 May; 26(5):700-7. PubMed ID: 23391620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.